CORT
Corcept Therapeutics Incorporated NASDAQ$51.60
Mkt Cap $5.5B
52w Low $28.66
36.8% of range
52w High $91.00
50d MA $39.31
200d MA $60.70
P/E (TTM)
54.1x
EV/EBITDA
51.2x
P/B
8.2x
Debt/Equity
0.0x
ROE
15.4%
P/FCF
25.5x
RSI (14)
—
ATR (14)
—
Beta
0.25
50d MA
$39.31
200d MA
$60.70
Avg Volume
1.7M
About
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 d…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.11 | -0.30 | -176.5% | 46.52 | +4.2% | +10.5% | — | — | — | — | — | — |
| Feb 24, 2026 | AMC | 0.33 | 0.20 | -39.4% | 36.48 | +3.2% | -0.7% | -1.9% | -2.1% | -1.4% | -3.3% | +5.6% | — |
| Nov 4, 2025 | AMC | 0.18 | 0.16 | -11.1% | 71.10 | -5.8% | +7.8% | +2.8% | +3.7% | +6.2% | +11.1% | +19.1% | — |
| Jul 31, 2025 | AMC | 0.23 | 0.29 | +26.1% | 67.17 | -3.6% | +2.7% | +6.8% | +4.9% | +5.0% | +6.4% | +6.3% | — |
| May 5, 2025 | AMC | 0.17 | 0.17 | +0.0% | 73.94 | -9.1% | -4.3% | -4.7% | -3.5% | -5.0% | -2.4% | -5.4% | — |
| Feb 26, 2025 | AMC | 0.37 | 0.26 | -29.7% | 63.37 | -3.7% | -5.6% | -4.4% | -6.8% | -11.6% | -12.4% | -13.8% | — |
| Oct 30, 2024 | AMC | 0.28 | 0.41 | +46.4% | 46.89 | -1.9% | +4.4% | +1.6% | +6.8% | +11.2% | +15.7% | +23.0% | — |
| Jul 29, 2024 | AMC | 0.23 | 0.32 | +39.1% | 36.53 | +5.1% | -1.1% | +5.9% | +3.9% | -3.4% | -5.5% | -5.7% | — |
| May 1, 2024 | AMC | 0.22 | 0.25 | +13.6% | 23.88 | +10.5% | +4.9% | +2.7% | +0.4% | +2.5% | +6.4% | +26.3% | — |
| Feb 15, 2024 | AMC | 0.26 | 0.28 | +7.7% | 24.46 | +6.3% | -7.2% | -7.7% | -11.4% | -6.0% | -8.2% | -0.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $46.52 | $48.48 | +4.2% | +10.5% | — | — | — | — |
| Mar 26 | Wolfe Research | Upgrade | Underperform → Peer Perform | — | $40.47 | $38.76 | -4.2% | -4.8% | -7.1% | -5.8% | -0.4% | +3.7% |
| Mar 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $40.47 | $38.76 | -4.2% | -4.8% | -7.1% | -5.8% | -0.4% | +3.7% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.82 | $34.15 | +1.0% | +19.7% | +13.9% | +11.2% | +12.7% | +19.2% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.48 | $37.65 | +3.2% | -0.7% | -1.9% | -2.1% | -1.4% | -3.3% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.24 | $33.97 | -0.8% | +1.7% | +3.2% | +6.5% | +5.8% | +4.5% |
| Jan 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $41.30 | $41.77 | +1.1% | +6.5% | +10.5% | +11.9% | +11.0% | +8.0% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.30 | $41.77 | +1.1% | +6.5% | +10.5% | +11.9% | +11.0% | +8.0% |
| Jan 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $34.80 | $35.76 | +2.8% | +9.8% | +0.4% | +2.8% | +6.3% | +5.0% |
| Jan 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.80 | $35.76 | +2.8% | +9.8% | +0.4% | +2.8% | +6.3% | +5.0% |
Recent Filings
8-K · 7.01
! Medium
Corcept Therapeutics Incorporated -- 8-K 7.01: Regulation FD Disclosure
Corcept Therapeutics disclosed Q1 2026 financial results and corporate updates via press release, providing investors with recent performance metrics and strategic developments.
Apr 30
8-K · 5.02
!!! Very High
Sagimet Biosciences Inc. Series A -- 8-K 5.02: Executive Change
Sagimet Biosciences' Chief Medical Officer Eduardo Martins resigned, potentially impacting clinical development leadership and investor confidence in the biotech company's pipeline progression.
Apr 21
8-K
Unknown — 8-K Filing
Corcept Therapeutics gained FDA approval for Lifyorli in a new oncology indication, expanding its market opportunity beyond Cushing's syndrome and potentially driving significant revenue growth from this first-in-class selective glucocorticoid receptor antagonist.
Mar 25
8-K · 7.01
! Medium
Corcept Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure
Corcept Therapeutics disclosed Q4 2025 financial results and corporate updates via press release, providing investors with recent performance metrics and forward guidance for the pharmaceutical company.
Feb 24
8-K
Corcept Therapeutics Inc. -- 8-K Filing
Corcept Therapeutics lost a Federal District Court appeal in New Jersey, upholding a December 2023 verdict that may have negative financial or legal implications for the company's operations or intellectual property.
Feb 19
Data updated apr 25, 2026 2:42am
· Source: massive.com